(24/7 MARKET NEWS) – Bionomics Limited (NASDAQ: BNOX) reported, this morning, that its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD achieved positive topline results. The ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks and was well-tolerated with a safety profile supporting chronic administration.
Bionomics Limited is trading at $1.92, up $0.935 (+94.92%%), on 3.7M premarket shares traded.
Its 52-week range is $0.93 to 10.90. Its next key inflection point is $2 and the only thing between that and $2.50 are a couple of price spike days.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.